Welcome to our dedicated page for Akumin news (Ticker: AKU), a resource for investors and traders seeking the latest updates and insights on Akumin stock.
Akumin Inc. (NASDAQ: AKU, TSX: AKU) is a leading provider of radiology and oncology services across 48 U.S. states, operating 180 imaging locations. This page aggregates essential updates for stakeholders tracking the company's financial performance, operational developments, and strategic partnerships.
Investors and analysts will find comprehensive coverage of earnings reports, merger activities, and transformational initiatives like the Stonepeak-backed restructuring plan. The curated news selection includes updates on clinical advancements, service expansions, and management strategies addressing healthcare industry challenges.
Key content focuses on verified financial data, partnership announcements with hospital networks, and operational efficiency measures. Regular updates provide insights into Akumin's progress in diagnostic imaging leadership and oncology care innovation while maintaining compliance with financial disclosure standards.
Bookmark this page for streamlined access to AKU's latest press releases and market-moving developments. Check back frequently for authoritative reporting on Akumin's journey as a national healthcare services partner.
Akumin Inc. (NASDAQ: AKU) reported its Q4 and full-year 2022 financial results on March 16, 2023. The company achieved Q4 revenue of $184.6 million, a 3% increase year-over-year, and full-year revenue of $749.6 million, up 78% due to the Alliance HealthCare Services acquisition. However, net losses for Q4 and the year rose to $49.3 million and $151.6 million, respectively, primarily due to increased interest expenses and goodwill impairment charges. Adjusted EBITDA for Q4 was $37.4 million, marking a 36% increase. Akumin expects 2023 revenue between $765-775 million and Adjusted EBITDA of $150-160 million, highlighting ongoing transformation initiatives.
Akumin Inc. (NASDAQ: AKU) will host a conference call on March 17, 2023, at 8:30 a.m. ET to discuss its year-end 2022 financial results. These results will be available on March 16, 2023. The company provides diagnostic imaging and oncology services to nearly 1,000 hospitals across 48 states. Participants can access the call via a designated dial-in number or through a webcast. A replay will be available until March 24, 2023. Akumin focuses on enhancing patient diagnosis and treatment through advanced technology and operational expertise.
Akumin Inc. (NASDAQ: AKU) announced the appointment of John Wagner and Lawrence Ross Sinclair to its board of directors, effective January 1, 2023. Wagner, a co-founder of SCW Capital Management, brings significant investor confidence, holding about 12.7% of Akumin's stock. Sinclair, a former partner at PwC with over 25 years of experience, is set to join the audit committee. The appointments aim to enhance board expertise in finance and strategy, which could aid Akumin's growth and service delivery across its radiology and oncology solutions to 1,000 hospitals in 48 states.
